Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. (ALMS) director and 10% owner James B. Tananbaum reported multiple open-market purchases of the company’s common stock. On November 17–19, 2025, entities he is associated with bought a total of 507,874 shares at prices ranging from $5.59 to $6.56 per share, increasing his indirect beneficial ownership in Alumis. The shares are held across several Foresite-affiliated investment vehicles, including Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Foresite Capital Fund V, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. Tananbaum reports potential voting and dispositive power through these entities but disclaims group status and beneficial ownership beyond his pecuniary interest.
Alumis Inc. (ALMS) director Srinivas Akkaraju reported open-market purchases of Alumis common stock made through affiliated investment funds.
On 11/17/2025, Samsara Opportunity Fund, L.P. bought 914 shares at a weighted average price of $5.51. On 11/18/2025, it purchased 102,652 shares at a weighted average of $6.05, and on 11/19/2025 it bought 137,772 shares at a weighted average of $6.56. After these transactions, the reporting person is deemed to beneficially own 517,517 shares held by Samsara Opportunity Fund, L.P. and 4,491,731 shares held by Samsara BioCapital, L.P., with beneficial ownership disclaimed except for any pecuniary interest.
Alumis Inc. (ALMS) director Srinivas Akkaraju reported an indirect purchase of common stock. On 11/13/2025, 276,179 shares of Alumis common stock were acquired at a price of $5.25 per share in a privately negotiated transaction. The shares were purchased by Samsara Opportunity Fund, L.P. from Samsara BioCapital, L.P., both investment entities with which the reporting person is affiliated.
Following this transaction, 276,179 shares are held through Samsara Opportunity Fund, L.P., and 4,491,731 shares are held through Samsara BioCapital, L.P. The filing notes that the transfer between these entities did not change the reporting person’s overall beneficial ownership, and that he disclaims beneficial ownership in these securities except to the extent of his pecuniary interest.
Alumis Inc. reported Q3 2025 results showing a net loss of $110.8 million as R&D spending of $97.8 million and G&A of $19.5 million outweighed $2.1 million of collaboration revenue. For the nine months, total revenue was $22.1 million (license $17.4 million; collaboration $4.7 million), and net loss was $150.4 million, reflecting a $187.9 million gain on bargain purchase from the ACELYRIN merger.
The company completed the ACELYRIN Merger on May 21, 2025, issuing 48,653,549 shares as consideration of $238.1 million for net assets with a fair value of $426.0 million, and recognized a $10.7 million deferred tax liability tied to acquired IPR&D.
As of September 30, 2025, cash and cash equivalents were $65.3 million and marketable securities were $312.5 million; stockholders’ equity was $384.8 million. Operating cash outflow for the nine months was $297.6 million. Management states the $377.7 million in cash, cash equivalents and marketable securities provides at least 12 months of funding. As of November 6, 2025, voting shares outstanding were 97,208,495 and non‑voting shares were 7,184,908.
Alumis Inc. filed a current report stating that it issued a press release on November 13, 2025, to announce its financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and provides details on the company’s operations and financial condition for the period.
The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. The report is signed by Martin Babler, President and Chief Executive Officer of Alumis Inc.
Alumis Inc. filed a current report to note that it has updated its corporate presentation for use in meetings with investors, analysts, and other audiences as of September 2025. The updated presentation is included as Exhibit 99.1 to the report on Form 8-K.
The company states that the information in the report and the attached presentation is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not automatically be incorporated by reference into other securities law filings unless specifically referenced.
Alumis Inc. completed the ACELYRIN merger and significantly strengthened its balance sheet. Total assets rose to $610.9 million from $341.0 million at year-end, and combined cash, cash equivalents and marketable securities totaled approximately $486.3 million as of June 30, 2025. The company issued 48,653,549 shares (about $238.1 million consideration) to acquire ACELYRIN, adding the lonigutamab program and an IPR&D intangible asset valued at ~$51.0 million. The acquisition produced a $187.9 million gain on bargain purchase, which turned the quarter to a $59.3 million net income result.
Operationally Alumis remains a development-stage, cash-consuming biopharma. Revenue was $2.7 million for the quarter ($20.1 million six months) while research and development expense rose to $108.8 million in the quarter and operating cash used was $186.7 million for the six months. The company had an accumulated deficit of $698.2 million and states existing resources should fund operations for at least 12 months, though additional capital will be needed thereafter.
Alumis Inc. furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states that the information in Item 2.02 and Exhibit 99.1 is furnished and therefore is not deemed to be "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is signed by Martin Babler, President and Chief Executive Officer.